The American College of Cardiology (ACC) expert decision pathway for chest pain can safely and effectively rule out acute ...
Bystander use was zero in at-home OHCAs and < 20% in public, even when an AED was less than a 1-minute walk away.
The researchers note that PCSK9 inhibitors have been shown to reduce CV risk in patients with high Lp (a) levels while ...
Only a minority of patients are prescribed triple therapy and even fewer are prescribed quadruple therapy at the time of ...
The trial, though not powered for clinical outcomes, hints at yet another setting where it may be possible to leave nothing ...
The injectable activin signaling inhibitor is the first of this class to be approved by the FDA and is meant to be given ...
As researchers learn more about the link between pregnancy complications and CV risk, lifestyle modifications may prove key.
Imaging allows “us to ‘measure twice, cut once,’ ensuring the highest level of precision in these critical interventions,” ...
Though they come with caveats, the results suggest QCA could fill a niche for operators who don’t use intravascular imaging.
Ticagrelor may be limited by cost and a twice-daily formulation, but it lowers both ischemic and bleeding risk vs clopidogrel ...
A suggestion of reduced mortality with paclitaxel devices compared with controls requires more study, says Sahil Parikh.
Aprocitentan is a novel endothelin receptor antagonist, the first agent approved in this class, and is indicated for use in ...